Latest news with #Solid
Daily Mirror
5 days ago
- Entertainment
- Daily Mirror
Hollywood legend Michael Douglas reveals worrying reason he hasn't worked for 3 years
Fatal Attraction and Ant-Man actor Michael Douglas has shared his fear of ending up as 'one of those people who dropped dead on set' after marking a milestone birthday His Hollywood legend father Kirk Douglas carried on working into his nineties, but Michael Douglas says he's happy to 'play the wife' and step away from his acting career at a comparatively youthful 80. Speaking to Best Magazine, Michael explains that he hasn't actually worked for a few years, and while he hasn't definitively retired, it would take a very special script to lure him back into the studio: 'I say I'm not retired, because if something special came up, I'd go back.' For now, though, he says he's happy to watch his wife, Catherine Zeta-Jones, 55, go out to work, while he enjoys his remaining years in peace: 'I did not want to be one of those people who dropped dead on set,' he joked. Welsh-born Catherine, some 25 years younger than her husband, is still keeping herself very busy, with a variety of film and TV projects on the boil, including Netflix 's hit series Wednesday. As he winds down from his acting career, though, Michael has reason to be grateful for his old age. In 2010, he was diagnosed with cancer of the tongue. The reality behind the diagnosis wasn't made public at the time, with his doctor advising that it would be better to describe his condition as throat cancer, because of the possible negative publicity that might arise from him having such a disfiguring and potentially deadly condition. He later explained on This Morning that he felt he had to make some sort of announcement, because his treatment meant he had to pull out of a publicity tour for the movie Wall Street: Money Never Sleeps. He recalled: 'The surgeon said let's just say it's throat cancer. I said 'OK, you don't want to say it's tongue cancer?', I said 'Why's that?' and he said 'Well, if you really want to know why, if we do have to have surgery it's not going to be pretty. You'll lose part of you jaw and your tongue and all of that stuff.' So I said, 'OK sure.'" Aggressive chemotherapy sent the cancer into remission, but Michael admits that he went through a very tough time: 'Stage four cancer is not a holiday. You know? It's not a holiday. But there aren't many choices, are there? 'I went with the program involving chemo and radiation, and was fortunate. I had a couple of friends during that same time who were not so lucky.' He mentions Dallas star Larry Hagman, and songwriter Nickolas Ashford – who had a huge hit with 'Solid' in 1984 – as being diagnosed with the same condition at roughly the same time. Sadly, neither of them survived. Michael says that his cancer had probably been brought about by a combination of stress, alcohol abuse, and years of heavy smoking – although, at the time, an offhand remark during an interview with the Guardian led to stories that the main trigger for his cancer had been an infection of the HPV virus, caused by performing oral sex.
Yahoo
08-07-2025
- Business
- Yahoo
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA - - Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 - - Expands Solid's clinical pipeline to include first cardiac indication with urgent unmet medical need - CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the 'Company' or 'Solid'), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) and clinical trial application (CTA) by Health Canada for SGT-501, a novel gene therapy approach for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), a highly malignant, arrhythmogenic channelopathy caused by genetic mutations that impact the ryanodine receptor (RYR2) in cardiac muscle. The Company expects to initiate a Phase 1b clinical trial to evaluate the safety, tolerability and efficacy of SGT-501 in the fourth quarter of 2025. Gabriel Brooks, M.D., Chief Medical Officer of Solid, said: 'Despite being identified nearly 50 years ago, CPVT still lacks FDA-approved therapies – this announcement reflects a critical development in the treatment of this underserved, often fatal, cardiac disease. SGT-501 offers a precision genetic approach targeting the underlying pathophysiology of the disease: abnormal calcium releases from the sarcoplasmic reticulum in an otherwise structurally sound heart. We believe SGT-501 has the unique potential to provide durable protection and may be capable of liberating patients from the ever-present threat of lethal arrhythmias and life-limiting prohibitions on exercise. Solid is proud to launch this program to help address this clear unmet need, further expanding our pipeline of differentiated and thoughtfully designed genetic medicines.' Silvia Priori, M.D., Ph.D., Professor of Cardiology at the University of Pavia and Director of the Molecular Cardiology Unit at the IRCCS Maugeri in Pavia, Italy, said: 'After decades during which we, the clinical community, have been limited in our ability to treat people living with CPVT, I have long hoped for the day when a genetic-modifying therapy becomes available. We are proud to partner with Solid who advanced fundamental work from our labs at Maugeri, which demonstrated the principle that calsequestrin overexpression can have a therapeutic impact on multiple forms of CPVT in both cellular and mouse models of disease. This work was further developed into a compelling IND safety and efficacy package through close collaboration with, and studies conducted by, the Solid team. I look forward to clinical updates for SGT-501 and seeing how this potential medicine may benefit people living with CPVT who are in critical need of disease-specific medicines.' About SGT-501SGT-501 is an AAV-based gene therapy candidate designed to deliver a functional, full length, codon-optimized copy of the human cardiac calsequestrin (CASQ2) gene to heart muscle cells. In the context of RYR2 variants, increasing CASQ2 protein levels enhances buffering of free calcium in the sarcoplasmic reticulum, stabilizing the RYR2, which results in reduced diastolic calcium leak into the cytosol. Stabilization of the RYR2 in its closed conformation supports the maintenance of normal cardiac rhythm with the potential to protect against ventricular tachycardia. SGT-501 received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. FDA and has potential as a first-in-class therapy to correct the underlying RYR2 instability and calcium dysregulation causes of CPVT. The AAV-CASQ2 gene therapy approach utilized by SGT-501 was pioneered by Dr. Silvia Priori and the IRCCS ICS Maugeri lab in Pavia, Italy. As a globally recognized leader in inherited arrhythmias, Dr. Priori has long been at the forefront of translational cardiac research. Solid Biosciences in-licensed this innovative therapeutic in 2023 and subsequently advanced it into IND-enabling preclinical development, marking an important step toward bringing this potential treatment to individuals living with CPVT. About Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a heart condition marked by abnormal rhythms; specifically, an abnormally fast heartbeat (ventricular tachycardia), which can be triggered by adrenergic stimulation such as physical activity or emotional stress. These arrhythmias can cause unexplained fainting, seizures, cardiac arrest and sudden death. CPVT is estimated to affect roughly 1 in 10,000 individuals globally, although it is often misdiagnosed, and is typically identified in children and young adults. It is mainly caused by mutations in the RYR2 and CASQ2 genes, which disrupt calcium regulation in heart muscle cells, impairing proper heart contraction and relaxation. There are currently no treatments that address the underlying mechanisms of CPVT. To learn more about CPVT and SGT-501, watch a brief CPVT expert and patient video by clicking here. About Istituti Clinici Scientifici Maugeri Spa SB (ICS Maugeri)ICS Maugeri S.p.A. Società Benefit is Italy's leading healthcare provider specializing in rehabilitation and comprehensive care for vulnerable patients. It stands out for its strong focus on scientific research, operating 18 Clinical Institutes - including 9 recognized as IRCCS (Scientific Institutes for Research, Hospitalization and Healthcare) and 9 as Scientific Clinical Institutes -along with 6 outpatient centers, 1 Environmental Research Center, and a Poison Control Center and National Toxicology Information Center. ICS Maugeri is involved not only in scientific research but also in the application of advanced technologies across medical disciplines, offering personalized care pathways and centers of excellence for specific conditions and clinical specialties. The Group employs more than 4,000 professionals, where medical and professional excellence is intrinsically linked to core values of equity, inclusivity, equality, and transparency - principles that have always guided Maugeri's mission. Headquartered in Pavia, ICS Maugeri operates 23 healthcare facilities across 7 Italian regions, including 9 IRCCS, 10 Scientific Clinical Institutes, 5 outpatient clinics, a Poison Control Center –Toxicology Center, and an Environmental Research Center. About Solid BiosciencesSolid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich's ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid's mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit Forward-Looking StatementsThis press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the Company; the ability to successfully achieve and execute on the company's goals, priorities and achieve key clinical milestones; the Company's pipeline of programs for neuromuscular and cardiac diseases, including its SGT-501, SGT-212 and SGT-003 programs and expectations for CTA filings, site activations, clinical development, initiation and enrollment in clinical trials, dosing, availability of clinical trial data and potential accelerated approval; the sufficiency of the Company's cash, cash equivalents, and available-for-sale securities to fund its operations; and other statements containing the words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'would,' 'working' and similar expressions. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the company's ability to advance SGT-501, SGT-212, SGT-003, SGT-601, SGT-401 and other preclinical programs and capsid libraries on the timelines expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; replicate in clinical trials positive results found in preclinical studies and early-stage clinical trials of the company's product candidates; obtain, maintain or protect intellectual property rights related to its product candidates; compete successfully with other companies that are seeking to develop Duchenne, Friedreich's ataxia and other neuromuscular and cardiac treatments and gene therapies; manage expenses; and raise the substantial additional capital needed, on the timeline necessary, to continue development of SGT-501, SGT-212, SGT-003, SGT-601, SGT-401 and other candidates, achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company's actual results to differ from those contained in the forward-looking statements, see the 'Risk Factors' section, as well as discussions of potential risks, uncertainties and other important factors, in the company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company's views as of the date hereof and should not be relied upon as representing the company's views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. Solid Biosciences Investor Contact:Nicole AndersonDirector, Investor Relations and Corporate CommunicationsSolid Biosciences Media Contact:Yuliya Kutuzava FINN in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
30-06-2025
- Business
- Associated Press
Affordable Ceretone OTC Hearing Aids Now Available at Target Stores Nationwide
LOS ANGELES, June 30, 2025 /PRNewswire/ -- Ceretone, a pioneering force in affordable hearing technology, today announces the nationwide launch of its over-the-counter (OTC) hearing aids at Target stores and The company has established itself as a leading OTC hearing aid brand in major retail channels, demonstrating strong consumer demand for accessible hearing aids. This collaboration brings five innovative Ceretone hearing aid models to Target customers nationwide: Torch, Style, Solid, Core One, and Beacon. The lineup addresses diverse hearing requirements and budget considerations across different consumer segments. Target stores will carry three models in-store, with two additional options available through A Hearing Aid for Everyone Torch: Features tinnitus masking and superior audio quality powered by advanced chips commonly used in prescription hearing aids, combined with simple operation and comfortable wear for users seeking professional-grade performance, all at a fraction of the price. Price: $249.99 Style: Delivers excellent sound quality with a fashionable design that appeals to consumers who prioritize both aesthetics and functionality, representing the most affordable option in the lineup. Price: $99.99 Solid: Offers unique charging-while-drying functionality, large physical buttons designed for senior-friendly operation, and represents excellent value for budget-conscious consumers. Price: $199.99 Core One: The world's smallest and 99% invisible hearing aid with exceptional comfort and app control. The upgraded Core One Pro will be launched in July, with exciting new features to be revealed soon. Price: $329.99 Beacon: Ceretone's flagship behind-the-ear model with advanced self-fitting and streaming functions, delivering superior sound quality and seamless connectivity to your digital devices. Price: $599.99 Accessibility to Better Hearing The company's proven track record in the retail hearing aid market has demonstrated strong consumer acceptance and paved the way for this exciting partnership with Target. 'Our R&D team brings years of experience from the prescription hearing aid world, which gives us a real advantage in the OTC market,' said Lincoln Lee, Ceretone's Product Director. 'We're focused on delivering better performance and quality at lower costs - that's how we make sure our customers get more for less, so more Americans can access quality hearing solutions.' About Ceretone: Founded by an engineer whose father experienced hearing loss due to the prohibitive cost and poor performance of available hearing aids, Ceretone was created to address these challenges for others. The company is driven to develop high-performance, affordable hearing aids that everyone can access. View original content to download multimedia: SOURCE Ceretone
The Hindu
27-06-2025
- General
- The Hindu
NGT directs Coimbatore Corporation to clear legacy waste at Vellalore dumpyard by year-end
The National Green Tribunal (Southern Zone), in a hearing held on June 23, 2025 (Monday), directed Coimbatore Corporation to carry out waste segregation on a war footing and clear the legacy waste at the Vellalore dump yard by the end of 2025. The Corporation has been asked to submit a time-bound action plan in consultation with the Committee headed by the Additional Chief Secretary to the Department of Municipal Administration and Water Supply, which is monitoring the implementation of Solid, Liquid and Other Waste Management Rules. During the hearing, the Tribunal noted that the segregation percentage had dropped from 36% in November 2023 to 15% in May 2025, while the volume of processed waste increased 64% to 85%. The Corporation stated that only three trommels were being used, which the Tribunal termed inadequate for handling the volume of legacy waste, estimated at over 9.9 lakh metric tonnes as of December 2024. The Tribunal questioned the delay and called for the use of additional trommels or advanced machinery such as the Power Screen Warrior 1200 to increase daily processing capacity to at least 10,000 tonnes. It also sought a more detailed report on plantation activities on reclaimed land and instructed the Tamil Nadu Pollution Control Board to carry out monthly inspections and submit reports. The matter has been posted for further hearing on August 7, 2025.
Yahoo
10-06-2025
- Entertainment
- Yahoo
iHeartMedia and Charlamagne Tha God Announce The Drink Champs Podcast Network in Partnership with The Black Effect
The Drink Champs Podcast Network in Partnership with The Black Effect to feature a new slate of original podcasts executive produced by N.O.R.E and EFN that explore the dynamic intersection between hip-hop, culture and creativity The new podcast network debuts its first show, "ROC SOLID with Memphis Bleek" Listen to "ROC Solid" now HERE NEW YORK, June 10, 2025 /PRNewswire/ -- iHeartMedia, the No. 1 podcast publisher globally according to Podtrac, and Charlamagne Tha God's The Black Effect Podcast Network today announced the launch of The Drink Champs Podcast Network in Partnership with The Black Effect, a new home for culture-shifting conversations and original content rooted in hip-hop and beyond. All content on the new network will be executive produced by Drink Champs' hosts N.O.R.E. and DJ EFN, known for their captivating storytelling and dynamic interviews. From debuting their show nine years ago to amassing nearly 100 million downloads, legendary Queens rapper N.O.R.E and Miami Hip Hop pioneer DJ EFN have firmly established themselves as ones-to-watch in the podcasting space with "Drink Champs." Now, with the launch of The Drink Champs Podcast Network in Partnership with The Black Effect, they are set to amplify new voices, elevate untold stories and expand the legacy of culturally impactful storytelling rooted in hip-hop. "We're eager to share all we've learned over the years in helping trailblaze in this space," said Drink Champs co-hosts N.O.R.E. and DJ EFN. "Our goal is to set people up not only for success, but with the tools to forge their own lanes." "This collaboration between The Black Effect Podcast Network and 'Drink Champs' represents something special within the podcasting world," said Dollie S. Bishop, President, The Black Effect Podcast Network. "We're merging the energy and authenticity of hip hop culture with the vast reach of iHeartMedia, creating a unique platform for storytelling and culture-rich conversations. Our shared vision allows us to create a platform that not only amplifies the voices in music and hip hop but also connects with our audience on a deeper level." The network will debut with, "ROC Solid," a new original podcast series hosted by hip-hop icon and Roc-A-Fella Records legend Memphis Bleek. After decades of making waves in the music industry, Bleek is flipping the script in "ROC Solid," and now he's the one asking the questions. The new original series will highlight voices from Bleek's Roc-A-Fella past including N.O.R.E., Young Guru, Freeway, Lenny S, and more, and will expand beyond the music label to feature raw, unfiltered conversations about what it truly means to be solid. This isn't just a Roc-A-Fella retrospective, it's a platform for culture-shapers across music, business, sports, and beyond who've made a lasting impact. "After everything I've seen, done, and built in this game, it's time to tell the real stories and hear from others who've stayed true to theirs," said Bleek. "'ROC SOLID' is about more than music. It's about the mindset, the moves, and the moments that define greatness." "We are excited to officially launch our network in partnership with iHeartMedia and The Black Effect Podcast Network, with 'ROC Solid' hosted by Memphis Bleek as the first show," said DJ EFN. "It's only natural that Bleek – a 'Drink Champs' fan favorite and repeat guest would be the host of our debut show." In celebration of Black Music Month, the series will kick off with a special debut episode featuring Ja Rule. In the no-holds-barred conversation, Bleek and Ja will reflect on their journeys as rap artists, Roc-A-Fella memories, and the state of the culture today. "Launching the network with 'ROC Solid' feels like the perfect fit. It's the kind of show that gets to the heart of the music industry with raw stories, real voices and a lot of truth," said Bishop. Additional shows on The Drink Champs Podcast Network in Partnership with The Black Effect will be announced later but will include a diverse range of content that resonates with hip hop fans everywhere. "ROC Solid" and all shows on The Drink Champs Podcast Network in Partnership with The Black Effect will be distributed by iHeartPodcasts and will be available on the iHeartRadio app and everywhere podcasts are heard. To learn more about "Drink Champs" visit: View original content: SOURCE iHeartMedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
